
Theravance Biopharma (TBPH) Stock Forecast & Price Target
Theravance Biopharma (TBPH) Analyst Ratings
Bulls say
Theravance Biopharma demonstrated a notable revenue increase of 6.8% in the fourth quarter of 2023, reaching $18.8 million, driven by a strong performance in hospital doses, which grew by 49% year-over-year. The company’s commitment to expanding its hospital channel is expected to support further sales growth into 2025, supported by the strong momentum of its FDA-approved product, YUPELRI, which has shown exceptional growth in hospital accounts. Additionally, potential future approvals could enhance revenue through milestone payments and tiered royalties, indicating a promising outlook for the company’s financial performance.
Bears say
Theravance Biopharma Inc. reported a non-GAAP loss per share of $0.05, which was under the company's own estimate as well as the street consensus, indicating weaker financial performance than anticipated. The company also faced a loss on extinguishment of debt, which added financial strain. Additionally, the challenges associated with forecasting revenues following loss of exclusivity (LOE), compounded by the complexities of developing generic versions of their triple-combination therapy, raise concerns about the sustainability of cash flows in the future.
This aggregate rating is based on analysts' research of Theravance Biopharma and is not a guaranteed prediction by Public.com or investment advice.
Theravance Biopharma (TBPH) Analyst Forecast & Price Prediction
Start investing in Theravance Biopharma (TBPH)
Order type
Buy in
Order amount
Est. shares
0 shares